Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. However, there is no data on the safety and efficacy of CAR T-cell therapy in patients with end stage renal disease (ESRD) requiring dialysis. In this report, we present two pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Bradley D., Hoda, Daanish, Nguyen, Andy, Gouw, Launce, Huber, Bryan, Jensen, Ryan R., Preedit, Justine, Evens, Andrew, Huang, Esther, Park, Jiyeon, Cooper, Dennis L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883625/
https://www.ncbi.nlm.nih.gov/pubmed/35227310
http://dx.doi.org/10.1186/s40164-022-00266-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883625/
https://www.ncbi.nlm.nih.gov/pubmed/35227310
http://dx.doi.org/10.1186/s40164-022-00266-1

Ejemplares similares